Patents Issued in March 28, 2024
-
Publication number: 20240101571Abstract: Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.Type: ApplicationFiled: October 9, 2023Publication date: March 28, 2024Inventors: Raju MOHAN, John NUSS, Jason HARRIS, Shendong YUAN
-
Publication number: 20240101572Abstract: The present invention provides a compound having a PLD inhibitory activity. The present invention provides a compound of the following structural formula, and the like, or a pharmaceutically acceptable salt thereof. wherein each symbol is as defined in the description.Type: ApplicationFiled: June 15, 2023Publication date: March 28, 2024Inventors: Masahiro YOKOTA, Tetsudo KAYA, Makoto TORIZUKA, Yasuaki NAKAYAMA, Taku IKENOGAMI, Katsuya MAEDA, Kazuki OTAKE, Kentaro SAKURAI
-
Publication number: 20240101573Abstract: A macrocyclic K-RAS G12C inhibitor, a preparation method therefor and use thereof. The inhibitor can be widely used in preparation of a drug for treating cancer or tumor which is at least partially mediated by a K-RAS G12C mutation, particularly a drug for treating lung, liver, gastrointestinal tract, blood system, skin, bone, genitourinary tract, nervous system, gynecological, and adrenal related malignant tumor or cancer.Type: ApplicationFiled: October 18, 2021Publication date: March 28, 2024Inventors: Guoliang XUN, Hongping YU, Zhui CHEN, Yaochang XU
-
Publication number: 20240101574Abstract: The present invention relates to a polysubstituted imidazolo[4,5-c][1,2]thiazine derivative and a use of an agent comprising same as an active agent, which is useful for infectious diseases associated with vascular inflammation caused by HMGB1 protein activity. It has been found that the polysubstituted imidazolo[4,5-c][1,2]thiazine derivative of the present invention increases the sepsis survival rate as a result of searching for antiseptic effects through CLP-induced sepsis animal experiments. Accordingly, the agent comprising the polysubstituted imidazolo[4,5-c][1,2]thiazine derivative or a pharmaceutically acceptable salt thereof as an active agent may be advantageously used as a therapeutic agent for infectious diseases and vascular inflammatory diseases including sepsis caused by HMGB1 protein activity.Type: ApplicationFiled: December 6, 2021Publication date: March 28, 2024Applicant: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Taeho LEE, Jong-Sup BAE, Sangkyu LEE, Hyun Chae SIM, Ji Min MOON
-
Publication number: 20240101575Abstract: The present invention relates to a method for preparing an enantiomerically enriched form of 3-(2-chlorothiazol-5-yl)-8-methyl-7-oxo-6-phenyl-2,3-dihydrothiazolo[3,2-a]pyrimidin-4-ium-5-olate.Type: ApplicationFiled: January 21, 2022Publication date: March 28, 2024Inventors: Christopher Koradin, Martin John McLaughlin, Roland Goetz, Rahul Kaduskar, Harish Shinde
-
Publication number: 20240101576Abstract: This disclosure provides chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit epidermal growth factor receptor (EGFR, ERBB 1) and/or Human epidermal growth factor receptor 2 (HER2, ERBB2). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) EGFR and/or HER2 activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.Type: ApplicationFiled: October 8, 2021Publication date: March 28, 2024Inventors: Angel Guzman-Perez, Benjamin C. Milgram, Ryan D. White, David St. Jean, JR.
-
Publication number: 20240101577Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.Type: ApplicationFiled: February 17, 2023Publication date: March 28, 2024Inventors: Elena S. KOLTUN, Naing N. AAY, Andreas BUCKL, Kevin T. MELLEM, Brian R. BLANK, Jennifer PITZEN, Gang WANG, Ashutosh S. JOGALEKAR, Walter S. WON, Christos TZITZILONIS, Jie Jack LI, Adrian Liam GILL, James Joseph CREGG
-
Publication number: 20240101578Abstract: The present disclosure provides a novel compound represented by the following Chemical Formula 1, and an organic light emitting device including the same: wherein A1 to A4, X, Y, n1 and n2 are described herein.Type: ApplicationFiled: March 8, 2022Publication date: March 28, 2024Applicant: LG Chem, Ltd.Inventors: Byeong Yun Lim, Jaechol Lee, Yongwook Kim, Soyoung Yu, Shin Sung Kim, Young Kwang Kim, Hyungil Park
-
Publication number: 20240101579Abstract: The present invention relates to a compound represented by Formula 1, a pharmaceutically acceptable salt thereof, or an isomer thereof, and a pharmaceutical composition for treating or preventing proteasome-mediated diseases, comprising the same as an active ingredient.Type: ApplicationFiled: December 10, 2021Publication date: March 28, 2024Applicant: LG CHEM, LTD.Inventors: Cheol Kyu JUNG, Seung Wan KANG, Byung Gyu KIM
-
Publication number: 20240101580Abstract: Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for treating a subject in need thereof with a bacterial infection.Type: ApplicationFiled: September 27, 2023Publication date: March 28, 2024Inventors: Christopher J. BURNS, Daniel C. PEVEAR, Luigi XERRI, Timothy HENKEL, Daniel MCGARRY, Lawrence ROSEN, Gerald BRENNER, Jean-Baptiste ARLIN, Ana FERNANDEZ CASARES
-
Publication number: 20240101581Abstract: An organic molecule is disclosed having a structure of Formula I: wherein n is 0 or 1; m=1?n; X is N or CRX; V is N or CRV; Z is N or CRII; R 1 and R 2 are independently from each other selected from the group consisting of: —C1-C5-alkyl, which is optionally substituted with one or more substituents R6; —C6-C60-aryl, which is optionally substituted with one or more substituents R6, and —C3-C57-heteroaryl, which is optionally substituted with one or more substituents R6.Type: ApplicationFiled: November 27, 2023Publication date: March 28, 2024Inventors: Nico-Patrick Thöbes, Thomas Baumann
-
Publication number: 20240101582Abstract: The compounds of the present disclosure have been developed and synthesized to generate compounds that provide improvements in film applications, such as HfOx, ZrOx, and TiOx film applications. The improvements to the compounds of the present disclosure include increased molecule stability at delivery temperature and deposition temperature, improvements related to precursor film impurity levels, molecule volatility, molecule melting point, and step coverage.Type: ApplicationFiled: August 29, 2023Publication date: March 28, 2024Inventors: Drew Michael Hood, Thomas M. Cameron
-
Publication number: 20240101583Abstract: Some embodiments relate to a precursor comprising a precursor for vapor deposition. The precursor comprises an aliphatic hydrocarbon and at least one disilylamine group. The at least one disilylamine group is attached to the aliphatic hydrocarbon. The at least one disilylamine group does not comprise a silanide group. Some embodiments relate to a method for making the precursor. The method comprises reacting a polyamine compound and a silylhalide compound in a presence of a base to form a precursor useful for vapor deposition. Some embodiments relate to a method for forming a silicon-containing film using the precursor.Type: ApplicationFiled: November 15, 2023Publication date: March 28, 2024Inventors: MinSeok Ryu, YeRim Yeon, JoongKi Choi, JongWon Nam, Sangbum Han
-
Publication number: 20240101584Abstract: 1, 2, 4, 5-tetraoxane compounds and derivatives thereof that have anticancer properties are disclosed. Pharmaceutical compositions and pharmaceutical formulations in unit dosage form suitable for the delivery of the compounds to a subject in need thereof are disclosed. The pharmaceutical compositions or formulations may include one or more active agents in addition to the compounds, such as one or more additional anticancer agents. Methods for treating a cancer, reducing a cancer, or treating or ameliorating one or more symptoms associated with a cancer in a subject are also disclosed. The methods include (i) administering to a subject in need thereof an effective amount of the compound (s). The compound (s) can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. The compound can selectively kill cancer cells and/or cancer stem cells over non-cancerous cells by triggering ferroptosis in the cancer cells and/or cancer stem cells.Type: ApplicationFiled: January 29, 2022Publication date: March 28, 2024Applicant: Westlake UniversityInventors: Dan YANG, Ming Kwan WONG
-
Publication number: 20240101585Abstract: The present invention relates to chromen-4-one derivatives comprising a phosphonium quaternary group, and to associated multi-salts, solvates, prodrugs and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treatment and prevention of cancer.Type: ApplicationFiled: January 26, 2022Publication date: March 28, 2024Inventor: Dan Florin Stoicescu
-
Publication number: 20240101586Abstract: A pyridine pyrrole ruthenium coordination complex, a preparation method therefor and use thereof as a catalyst for electrocatalyzing ammonia oxidation to prepare hydrazine is provided. The pyridine pyrrole ruthenium coordination complex takes high-activity metal ruthenium as a central metal ion and compounds containing pyridine pyrrole with electron withdrawing/donating capability as ligands, and thus has relatively high catalytic activity for ammonia oxidation. High conversion rate and highly selective conversion of ammonia can be realized by applying the pyridine pyrrole ruthenium coordination complex to electrocatalytic ammonia oxidation in an organic solvent, with major products including H2, N2, N2H4.Type: ApplicationFiled: December 15, 2022Publication date: March 28, 2024Applicant: CENTRAL SOUTH UNIVERSITYInventors: Xiaoyi YI, Guo CHEN
-
Publication number: 20240101587Abstract: Disclosed herein are systems and methods for the purification of human milk oligosaccharides (HMOs). The HMOs can be purified from a suspension containing one or more of a bacterial biomass, cell fragments, small particles, and biomolecules. Advantageously, the solution can be pre-treated prior to centrifuging to form a clarified supernatant containing purified HMOs.Type: ApplicationFiled: December 17, 2021Publication date: March 28, 2024Inventors: Nikolay KHANZHIN, Marco WIESER, Jesper THØGERSEN
-
Publication number: 20240101588Abstract: Methods of preparing nicotinamide riboside and derivatives thereof.Type: ApplicationFiled: April 26, 2023Publication date: March 28, 2024Inventors: Marie MIGAUD, Philip REDPATH, Kerri CROSSEY, Mark DOHERTY
-
Publication number: 20240101589Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: W—X—Y—Z (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.Type: ApplicationFiled: October 7, 2021Publication date: March 28, 2024Inventors: DAVID JAMES HARDICK, Wesley Peter Blackaby, Elizabeth Jane Thomas, Frederick Arthur Brookfield, Jon Shepherd, Christian Bubert, Mark Peter Ridgill
-
Publication number: 20240101590Abstract: Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase-mediated replication of DNA or RNA polymerase-mediated transcription of RNA. In this manner, the unnatural nucleobases can be introduced in a site-specific way into oligonucleotides (single or double stranded DNA or RNA), where they can provide for site-specific cleavage, or can provide a reactive linker than can undergo functionalization with a cargo-bearing reagent by means of reaction with a primary amino group or by means of click chemistry with an alkyne group of the unnatural nucleobase linker.Type: ApplicationFiled: February 22, 2023Publication date: March 28, 2024Inventors: Floyd E. ROMESBERG, Denis A. MALYSHEV, Lingjun LI, Thomas LAVERGNE, Zhengtao LI
-
Publication number: 20240101591Abstract: The invention discussed in this application relates to vitamin B12-based compounds that are useful as quantitative standards, particularly for the assessment of vitamin B12 deficiency.Type: ApplicationFiled: December 6, 2023Publication date: March 28, 2024Inventor: Peter ANDERSON
-
Publication number: 20240101592Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein ring D and the substituents are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of using the compound of Formula (I) in the treatment of CNS-related disorders.Type: ApplicationFiled: November 22, 2021Publication date: March 28, 2024Inventor: Maria Jesus Blanco-Pillado
-
Publication number: 20240101593Abstract: Ursolic acid (UA) preparations and a self-nanoemulsifying drug delivery system (SNEDDS) composition containing at least one UA preparation selected from monopotassium ursolate (UAK), dipotassium ursolate (UAK2), monocholine ursolate (UAmC), dicholine ursolate (UAdC), pharmacological salts thereof, and mixtures thereof are provided. Methods for synthesizing UA preparations and delivering UA preparations to subjects in need thereof are also provided.Type: ApplicationFiled: February 4, 2022Publication date: March 28, 2024Inventor: Phillip GERK
-
Publication number: 20240101594Abstract: Described herein are protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.Type: ApplicationFiled: July 28, 2023Publication date: March 28, 2024Inventors: Amy HAN, Andrew J. MURPHY, William OLSON
-
Publication number: 20240101595Abstract: A one-pot method of multiple protein labeling that is suitable for protein footprinting is disclosed, along with systems, auxiliary devices, kits, and non-transitory computer readable mediums relating to the same. Hydroxyl radicals are maintained at a concentration for a length of time sufficient to both react with trifluoromethyl precursors and a protein of interest, where the reaction with the trifluoromethyl precursors further maintains a trifluoromethyl concentration for a length of time sufficient to react with the protein of interest. The multiplex labeling achieves significant improvements over the state of the art labeling methods, both by increasing the types of amino acids which can be labeled in a single experiment and by increasing the overall labeling coverage.Type: ApplicationFiled: February 4, 2022Publication date: March 28, 2024Inventors: Mark R. Chance, Janna Kiselar
-
Publication number: 20240101596Abstract: The object of the invention is a method for extracting, with high yield, phycobiliproteins from cyanobacterial and/or algal biomass, obtaining extracts in water or aqueous solutions characterised by high pigment concentration and a purity degree equal to or greater than the food/cosmetic grade (P?2). The method is based on a process characterised by a step of breaking down the cyanobacterial/algal cells by ultrasonication in an aqueous solution of ammonium sulphate, and simultaneous extraction of water-soluble compounds other than phycobiliproteins, followed by an extraction step of the phycobiliproteins using water or aqueous solutions.Type: ApplicationFiled: December 22, 2021Publication date: March 28, 2024Inventors: Rosaria LAUCERI, Graziella CHINI ZITTELLI, Giuseppe TORZILLO
-
Publication number: 20240101597Abstract: Protein separation can be provided based on a High Performance Countercurrent Membrane Purification (HPCMP), which can exploit highly selective diffusive transport across thin walls of a hollow fiber membrane for separation of proteins. Embodiments of an HPCMP system can separate mixtures of multiple proteins (e.g. separate BSA and Mb) or other biological material and provide high yields (e.g. achieving greater than 98% yield of both proteins with purification factors greater than 100-fold, etc.). Embodiments of a HPCMP system can be configured for high resolution separations in the preparation of biopharmaceuticals and natural protein products. Other embodiments can be utilized in other protein separation environments or biological material separation environments.Type: ApplicationFiled: August 30, 2021Publication date: March 28, 2024Inventors: Andrew Lawrence Zydney, Christopher J. Yehl
-
Publication number: 20240101598Abstract: The present invention relates to new methods for the purification of Fc-peptide fusion protein (peptibodies) derived from inclusion bodies after prokaryotic expression. In particular, it relates to chromatographic methods of the fusion peptides after refolding and dimerization comprising affinity capture, intermediate and polishing chromatographies. These methods facilitate the decrease of product-related impurities, such as sulfide variants or charge variants of the Fc-peptide fusion proteins in the final product. In addition, the present invention relates to specific conditions and selected buffers avoiding aggregation, precipitation, and degradation of the Fc-peptide fusion proteins. Finally, the methods of the present invention result in a formulated pharmaceutical composition or a pre-stage pharmaceutical composition containing an Fc-peptide fusion protein of high purity.Type: ApplicationFiled: December 17, 2021Publication date: March 28, 2024Inventors: Sebastian DAMEROW, Elisa MIR, László Zoltán BARANYAI, Zoltán SÜTÖ
-
Publication number: 20240101599Abstract: An object is to provide a synthetic culture medium not containing animal-derived components. In particular, an object is to provide a culture medium not containing animal-derived components but containing peptides that promote cell growth or contribute to promotion of protein production. A culture medium containing a peptide selected from the group consisting of Gly-Glu-Lys (GEK), Asp-Gly-Pro (DGP), Ala-Gly-Lys (AGK), Gly-Pro-Pro (GPP), Gly-Gly-Pro (GGP), Ala-Glu-Lys (AEK), Ala-Gly-Gly (AGG), Ala-Ser-Asn (ASN), and Glu-Gly-Lys (EGK) is provided.Type: ApplicationFiled: December 22, 2020Publication date: March 28, 2024Applicant: Maruhachi Muramatsu, Inc.Inventors: Yoshinori HOKARI, Natsuko NARAWA, Keita AOSHIMA, Harumi SUGIYA, Aya SEKINE
-
Publication number: 20240101600Abstract: The present disclosure discloses a fibroblast growth factor receptor (FGFR)-targeting antagonistic short peptide, namely a short peptide compound P48 with the amino acid sequence of Ser-Pro-Pro-Arg-Tyr-Pro-Gly-Gly-Gly-Ser-NH2, where the short peptide compound P48 inhibits an FGFR pathway to inhibit cell proliferation and migration.Type: ApplicationFiled: December 8, 2020Publication date: March 28, 2024Inventors: Xiaokun Li, Jianzhang Wu, Wulan Li, Lingzi Chen, Lei Fan, Yuepiao Cai
-
Publication number: 20240101601Abstract: The present invention provides bi-terminal PEGylated peptide conjugates that target an integrin such as ?v?6 integrin. In particular embodiments, the peptide conjugates of the present invention further comprise a biological agent such as an imaging agent or a therapeutic agent, e.g., covalently attached to one of the PEG moieties. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating integrin-mediated diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, chronic fibrosis, chronic obstructive pulmonary disease (COPD), lung emphysema, and chronic wounding skin disease. Compositions and kits containing the peptide conjugates of the present invention find utility in a wide range of applications including, e.g., in vivo imaging and immunotherapy.Type: ApplicationFiled: September 15, 2022Publication date: March 28, 2024Applicant: The Regents of the University of CaliforniaInventors: Sven H. Hausner, Julie L. Sutcliffe
-
Publication number: 20240101602Abstract: Provided is a peptide and method in preventing or treating infections caused by a wide spectrum of pathogens, including bacteria and fungus in hosts such as plants and animals. Methods of preventing or treating plant diseases and infection in animals are also provided.Type: ApplicationFiled: November 24, 2021Publication date: March 28, 2024Inventors: Rita P.Y. Chen, Chiu-Ping CHENG, Chien-Chih YANG, Kung-Ta LEE, Ying-Lien CHEN, Li-Hang Hsu, Hsin-Liang CHEN, Sung CHEN
-
Publication number: 20240101603Abstract: The present invention relates to an antibacterial peptide and an antibacterial compound targeting the Klebsiella pneumoniae VapBC toxin-antitoxin system, or their use.Type: ApplicationFiled: January 20, 2022Publication date: March 28, 2024Inventors: Sung Min KANG, Bong Jin LEE, Cheng Long JIN, Do Hee KIM
-
Publication number: 20240101604Abstract: Peptides that selectively bind ENAH (MENA) are described. The peptides are useful for treating certain cancers, such as triple negative breast cancer and for reducing resistance to taxane therapy.Type: ApplicationFiled: January 25, 2022Publication date: March 28, 2024Inventors: Theresa Hwang, Amy E. Keating, Meucci Ilunga, Sara Parker, Ghassan Mouneimne, Samantha Hill
-
Publication number: 20240101605Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for CD69 and provides a CD69-binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QK X21AFKX25X26LKD. The present disclosure also relates to the use of such a CD69-binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.Type: ApplicationFiled: December 21, 2021Publication date: March 28, 2024Inventors: John LÖFBLOM, Stefan STÅHL, Jonas PERSSON, Olof ERIKSSON, Olov KORSGREN
-
Publication number: 20240101606Abstract: Disclosed herein include methods, compositions, and kits suitable for use in thresholding of protein signals. There are provided, in some embodiments, synthetic protein circuits that respond to inputs only above or below a certain threshold concentration. In some embodiments, the threshold value itself is tunable. Methods of treating a disease or disorder characterized by aberrant signaling are provided in some embodiments.Type: ApplicationFiled: May 11, 2023Publication date: March 28, 2024Inventors: Lucy S. Chong, Ronghui Zhu, Xiaofei Ge, Michael B. Elowitz, Mark W. Budde
-
Publication number: 20240101607Abstract: Disclosed are methods and compositions for preventing, treating, and/or ameliorating one or more symptoms of inflammation in a mammal. In particular, viral vectors and medicaments containing them are disclosed, which are useful in the prophylaxis, therapy, or amelioration of symptoms of one or more inflammatory-mediated mammalian diseases, such as age-related macular degeneration (AMD), arthritis, Bechet's disease, Best macular dystrophy, corneal inflammation, diabetic retinopathy, drusen formation, dry AMD, dry eye, geographic atrophy, glaucomaocular neovascularization, Lupus erythematosus, macular degeneration, Mallatia Leventinese and Doyne honeycomb retinal dystrophy, nephritis, ocular hypertension, ocular inflammation, recurrent uveitis, Sorsby fundus dystrophy, vasculitis, vitreoretinopathy, wet AMD, or related disorders.Type: ApplicationFiled: May 9, 2023Publication date: March 28, 2024Applicant: University of Florida Research Foundation, IncorporatedInventors: Douglas Grant McFadden, Alfred S. Lewin, Alexandra Rose Lucas, Cristhian J. Ildefonso, Mohammed Masmudur Rahman
-
Publication number: 20240101608Abstract: The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g.Type: ApplicationFiled: December 4, 2023Publication date: March 28, 2024Applicant: CureVac SEInventors: Patrick BAUMHOF, Susanne RAUCH, Aleksandra KOWALCZYK, Johannes LUTZ, Edith JASNY, Benjamin PETSCH, Andreas THESS, Thomas SCHLAKE, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Sandra LAZZARO, Fatma FUNKNER, Wolfgang GROSSE
-
Publication number: 20240101609Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.Type: ApplicationFiled: December 12, 2023Publication date: March 28, 2024Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servi, Institute for Research in BiomedicineInventors: Baoshan Zhang, Guillaume Stewart-Jones, Tongqing Zhou, John Mascola, Kai Xu, Yongping Yang, Paul Thomas, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
-
Publication number: 20240101610Abstract: Variant factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of Neisseria meningitidis, compositions comprising such proteins, and methods of use of such proteins, are provided.Type: ApplicationFiled: October 24, 2023Publication date: March 28, 2024Inventor: Peter T. BEERNINK
-
Publication number: 20240101611Abstract: Certain embodiments of the disclosure are related to compositions and methods for producing proteins of interest in pigment deficient Bacillus cells. Certain other embodiments are related to compositions and methods for obtaining pigment deficient Bacillus cells. Certain other embodiments are related to compositions and methods for growing/cultivating/fermenting pigment deficient Bacillus cells. Certain other embodiments are therefore related to compositions and methods for producing, isolating, recovering and the like proteins of interest that are pigment deficient.Type: ApplicationFiled: February 22, 2022Publication date: March 28, 2024Inventors: Ryan L. Frisch, Ibrahim Halloum, Mikhail Karymov, Christopher John Webb
-
Publication number: 20240101612Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: ApplicationFiled: September 6, 2023Publication date: March 28, 2024Inventors: Ravi Anantha, Nathalie Cadieux, Thomas G. Evans, Michele Stone, Barry Walker
-
Publication number: 20240101613Abstract: Provided herein are oligomeric reagents, including oligomeric reagents of streptavidin or a streptavidin mutein, and compositions thereof and methods for manufacturing oligomeric reagents, including methods for reliably manufacturing oligomeric particle reagents of a desired size. In some cases, the reagents are oligomeric particle reagents containing a plurality of binding sites for agents, and thus the one or more agents are multimerized by reversibly binding to the oligomeric particle reagent, e.g., thereby creating a multimerized oligomeric particle reagent, having stimulatory agents multimerized thereon. Also provided are methods for using the oligomeric reagents for incubation or culturing, such as to induce stimulation of expansion (proliferation), activation, costimulation and/or survival, of a composition of cells such as a population of lymphocytes. In some aspects, the disclosure provides methods and reagents for the stimulation, e.g.Type: ApplicationFiled: November 22, 2023Publication date: March 28, 2024Applicant: Juno Therapeutics GmbHInventors: Thomas SCHMIDT, Christian STEMBERGER, Tom KOWSKI, Ken PRENTICE
-
Publication number: 20240101614Abstract: The present disclosure relates to synthetic biology and, in particular, the expression of heterologous proteins in a microbial cell, and engineered enzymes for achieving the same.Type: ApplicationFiled: August 24, 2023Publication date: March 28, 2024Applicant: Inscripta, Inc.Inventors: Amanda Reider Apel, Karolina Kalbarczyk, Drew Fraser Thacker
-
Publication number: 20240101615Abstract: Disclosed herein are designed heterodimer proteins, monomeric polypeptides capable of forming heterodimer proteins, protein scaffolds including such polypeptides, and methods for using the heterodimer proteins and subunit polypeptides for designing logic gates.Type: ApplicationFiled: January 23, 2023Publication date: March 28, 2024Inventors: Zibo CHEN, Scott Boyken, Sherry Bermeo, Robert A. Langan, David Baker
-
Publication number: 20240101616Abstract: A chimeric antigen receptor including: a binding domain, the full DAP 10 protein, the full DAP 12 protein, or a functional variant thereof, and a hook binding domain. Also, a vector system comprising one or more vector including: a nucleic acid comprising a nucleic acid sequence encoding a chimeric antigen receptor and optionally a nucleic acid encoding a hook fusion protein, preferably having a streptavidin core; wherein the nucleic acids are located on the same or on different vectors. Further, a lentiviral vector particles system, host cell and kit including the nucleic acids or vector system, and their use as a medicament, notably for immunotherapy.Type: ApplicationFiled: November 21, 2023Publication date: March 28, 2024Applicants: INSTITUT CURIE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Franck Perez, Zelia Gouveia, Sebastian Amigorena, Gaelle Boncompain
-
Publication number: 20240101617Abstract: The present invention relates to methods and compositions for stabilizing proteins. The invention provides compositions comprising at least one tardigrade disordered protein (TDP) and at least one heterologous polypeptide and/or peptide of interest. Further provided are methods for stabilizing proteins and for producing organisms and cells having increased tolerance to desiccation and/or drought.Type: ApplicationFiled: November 20, 2023Publication date: March 28, 2024Inventors: Thomas Christopher Clark Boothby, Robert Patrick Goldstein, Gary Joseph Pielak, Samantha Piszkiewicz, Alexandra Harrison Brozena
-
Publication number: 20240101618Abstract: The present invention relates to an isolated peptide consisting of a sequence of 3 to 39 amino acids derived from the amino acid sequence SEQ ID NO: 1, said peptide having a sequence of amino acids selected from the group consisting of: a) sequences of 3 to 39 amino acids comprising at least the residues 6 to 8 of SEQ ID NO: 1, and b) sequences of 3 to 39 amino acids having at least 70% identity with said sequence in a).Type: ApplicationFiled: August 3, 2023Publication date: March 28, 2024Applicants: INSTITUT NATIONAL UNIVERSITAIRE JEAN-FRANCOIS CHAMPOLLION, UNIVERSITE TOULOUSE III - PAUL SABATIER, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DE ROUEN-NORMANDIEInventors: Khaddouj Benmoussa, Elsa Bonnafe, Agnès Coste, Jérôme Leprince, Bernard Pipy, Michel Treilhou
-
Publication number: 20240101619Abstract: A protein with an activity of inhibiting angiogenesis and inflammation, and a specific structure, use, and preparation method thereof are provided. The protein can inhibit both angiogenesis and inflammation, and can prevent and alleviate ophthalmic diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), and pterygium to some extent based on a dual action mechanism.Type: ApplicationFiled: January 13, 2021Publication date: March 28, 2024Applicant: ZHAOKE (GUANGZHOU) OPHTHALMOLOGY PHARMACEUTICAL LTD.Inventors: Xiaoyi LI, Xiangrong DAI, Li FANG, Fang QIAN, Yinping YAN, Zicheng DAI, Luoyi LI
-
Publication number: 20240101620Abstract: Glycan-binding proteins, and compositions thereof, are generally described, including methods of making and using such proteins. The proteins may include scaffolds based on easily evolvable DNA-binding proteins, with binding sites able to specifically bind to mono- or disaccharides, such as monosaccharide-binding determinants, disaccharide-binding determinants, more complex carbohydrates, etc. In certain aspects, a protein may be generated starting from a small DNA-binding protein, such as Sso7d. Such glycan-binding proteins may have numerous applications, including in enzyme-linked immunosorbent assays (ELISAs), glycan characterization, cell selection, flow cytometry, histology, imaging, arrays, affinity purification, enzyme-linked visualization, binding to a target for pharmaceutical purposes, etc.Type: ApplicationFiled: January 26, 2023Publication date: March 28, 2024Applicant: Massachusetts Institute of TechnologyInventors: Barbara Imperiali, Cristina Zamora, Elizabeth Ward